Relief Therapeutics Holding AG
Not enough financial coverage to compute a composite score for RLFTD. This is typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available data still render below.
Companywww.relieftherapeutics.com
Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis.
- CEO
- Jack Weinstein
- IPO
- 2021
- Employees
- 69
- HQ
- Geneva, CH
Price Chart
Growth & Income
- Revenue
- $8.42M · 39.52%
- Net Income
- $-17,119,000 · 82.56%
- EPS
- $-1.36 · 83.71%
- Op Income
- $-18,885,000
- FCF YoY
- 82.90%
Performance & Tape
- 52W High
- $15.15
- 52W Low
- $3.60
- 50D MA
- $7.49
- 200D MA
- $10.38
- Beta
- -14.14
- Avg Volume
- 38
Get TickerSpark's AI analysis on RLFTD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our RLFTD Coverage
We haven't published any research on RLFTD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RLFTD Report →